Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shortened sofosbuvir + daclatasvir therapy for chronic hepatitis C in Vietnam
ISRCTN17100273Phase 3Completed
- Sponsor
- Imperial College London
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of sofosbuvir and daclatasvir in hepatitis C virus infection, sponsored by Imperial College London. Primary endpoints: SVR12 after first treatment without prior failure and First-line virologic failure definition. Started Feb 2019; status: completed.
02
Drugs
sofosbuvirdaclatasvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on ISRCTN17100273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17100273.